Sanofi to Consolidate Massachusetts Activities

The company will move 2,700 employees from around the region to Cambridge Crossing.

The Boston, MA area has been recognized as a center for biotech for some time now. The Cambridge Crossing (previously North Point) development located on the Cambridge–Somerville line in East Cambridge is rapidly becoming an important biotech hub within the region. Most recently French drug-maker Sanofi announced that it will be consolidating its activities in two buildings encompassing 900,000 square feet at the development site. The deal is the largest single lease deal in the city’s history.

The Cambridge Crossing development covers 45 acres in total. In addition to Sanofi, other residents will include the North American headquarters of Royal Philips and precision medicine biotech company Goldfinch Bio.

Sanofi will move approximately 2,700 employees from around the region to the site once it is completed, which is expected to be some time in 2021. Both administrative and R&D work will be performed there. One of the main reasons for choosing the location was the ability to work closely with others in the biopharmaceutical industry. “Our new Sanofi site will further anchor us in this unique ecosystem of innovators for years to come,” said Sanofi Genzyme’s Executive Vice President Bill Sibold.

Emilie Branch

Emilie is responsible for strategic content development based on scientific areas of specialty for Nice Insight research articles and for assisting client content development across a range of industry channels. Prior to joining Nice Insight, Emilie worked at a strategy-based consulting firm focused on consumer ethnographic research. She also has experience as a contributing editor, and has worked as a freelance writer for a host of news and trends-related publications